Breaking News Instant updates and real-time market news.

NKTR

Nektar

$37.50

-0.7 (-1.83%)

12:05
11/21/18
11/21
12:05
11/21/18
12:05

Nektar call volume above normal and directionally bullish

Bullish option flow detected in Nektar with 2,685 calls trading, 3x expected, and implied vol increasing almost 3 points to 67.02%. Jan-19 40 calls and May-19 50 calls are the most active options, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 0.02. Earnings are expected on February 28th.

  • 27

    Nov

NKTR Nektar
$37.50

-0.7 (-1.83%)

11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
11/08/18
HCWC
11/08/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar shares may have bottomed, says H.C. Wainwright
During last night's Q3 corporate update call, Nektar Therapeutics provided clarity on soon to be initiated Phase 3 programs, with a vital expansion cohort in second line non-small cell lung cancer, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While the renal cell carcinoma, bladder, and melanoma studies were telegraphed previously, "clarity was welcome news for the bulls," says Chattopadhyay. However, the analyst adds that RCC and melanoma remain very crowded and that the initiation of triplet studies, if successfully clinically, "would significantly add to the financial toxicity discussion, especially since NKTR-214 is likely to be marketed as a unique medicine." Chattopadhyay thinks the newly defined cohort of approximately 100 second-line NSCLC patients to the ongoing Pivot trial is key to sentiment around the NKTR-214 story during the second half of 2019. He attributes the recent pullback in Nektar shares to disappointment from the preliminary read from the SITC abstract. Nonetheless, with a host of trial initiations and multiple combination updates at disease specific conferences during 2019, the stock may have bottomed, Chattopadhyay writes. However, the analyst says that while the study initiations and data releases should "quell some fears," the data quality "needs a pickup." He keeps a Neutral rating on Nektar with a $47 price target.
11/11/18
PIPR
11/11/18
NO CHANGE
Target $125
PIPR
Overweight
Piper Jaffray bullish on Nektar, more confident in Phase III study success
Following Nektar's updated data from the melanoma cohort at SITC, Piper Jaffray analyst Tyler Van Buren says it is clear that everyone has been "too myopic" by solely focusing on overall response rates. Despite this, the analyst says that it was "encouraging to see" it actually increase to 53% following independent central radiology, and compares well to nivo monotherapy. More importantly, a 24% CR rate is "impressive" at this stage, he contends. The analyst argues that the more durable responses appear to be translating to improved mPFS as it is not nearly reached with the study having about 8 months of median follow-up. Van Buren reiterates an Overweight rating and $125 price target on the shares as he is now incrementally more confident in Phase III study success.
11/12/18
MZHO
11/12/18
NO CHANGE
Target $81
MZHO
Buy
Nektar updated data in melanoma patients encouraging, says Mizuho
Mizuho analyst Difei Yang views Nektar Therapeutics' updated data in melanoma patients over the weekend as encouraging. While the data did not meet the analyst's base-case scenario, as overall response rate remained roughly in-line with the prior data update, Yang says she's encouraged to see a deepening of responses evidenced by an increase in the number of complete responses since the last data update. She continues to see merit in the NKTR-214/Opdivo combo. Yang expects continued data updates in various tumor settings over the coming months to drive Nektar shares and keeps a Buy rating on the name with an $81 price target.

TODAY'S FREE FLY STORIES

NOK

Nokia

$5.89

-0.37 (-5.91%)

09:56
03/22/19
03/22
09:56
03/22/19
09:56
Options
Nokia option volume spikes as shares decline on compliance headlines »

Nokia option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

VTR

Ventas

$64.28

0.56 (0.88%)

, CAG

Conagra Brands

$26.16

0.34 (1.32%)

09:55
03/22/19
03/22
09:55
03/22/19
09:55
Options
Early notable gainers among liquid option names on March 22nd »

Notable gainers among…

VTR

Ventas

$64.28

0.56 (0.88%)

CAG

Conagra Brands

$26.16

0.34 (1.32%)

EQR

Equity Residential

$74.88

0.6675 (0.90%)

HCP

HCP

$31.83

0.18 (0.57%)

ETR

Entergy

$95.63

0.75 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 26

    Mar

  • 01

    May

09:55
03/22/19
03/22
09:55
03/22/19
09:55
General news
U.S. March Markit manufacturing PMI fell 0.5 ticks to 52.5 »

U.S. March Markit…

09:55
03/22/19
03/22
09:55
03/22/19
09:55
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

FITB

Fifth Third

$25.12

-0.31 (-1.22%)

09:52
03/22/19
03/22
09:52
03/22/19
09:52
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 23

    Apr

CHGG

Chegg

$39.01

-0.645 (-1.63%)

09:52
03/22/19
03/22
09:52
03/22/19
09:52
Hot Stocks
Breaking Hot Stocks news story on Chegg »

Chegg drops 2% to $38.68…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHGG

Chegg

$39.01

-0.645 (-1.63%)

09:51
03/22/19
03/22
09:51
03/22/19
09:51
Periodicals
Breaking Periodicals news story on Chegg »

Citron Research says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:50
03/22/19
03/22
09:50
03/22/19
09:50
Conference/Events
Stephens financial analysts to hold a luncheon meeting »

Analysts hold a…

09:50
03/22/19
03/22
09:50
03/22/19
09:50
Hot Stocks
Breaking Hot Stocks news story  »

Liberty TripAdvisor…

WSM

Williams-Sonoma

$59.48

0.26 (0.44%)

09:50
03/22/19
03/22
09:50
03/22/19
09:50
Options
In-the-money call buyers in Williams Sonoma at the opening bell »

In-the-money call buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Apr

  • 03

    Apr

09:50
03/22/19
03/22
09:50
03/22/19
09:50
General news
U.S. existing home sales preview: »

U.S. existing home sales…

GTLS

Chart Industries

$94.49

(0.00%)

09:46
03/22/19
03/22
09:46
03/22/19
09:46
Recommendations
Chart Industries analyst commentary  »

Chart Industries'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 28

    May

09:45
03/22/19
03/22
09:45
03/22/19
09:45
Hot Stocks
Breaking Hot Stocks news story  »

Liberty TripAdvisor…

09:45
03/22/19
03/22
09:45
03/22/19
09:45
General news
U.S. wholesale trade preview: »

U.S. wholesale trade…

09:45
03/22/19
03/22
09:45
03/22/19
09:45
General news
Wholesale Trade Inventories to be reported at 10:00 »

January Wholesale Trade…

09:45
03/22/19
03/22
09:45
03/22/19
09:45
General news
Existing Home Sales to be reported at 10:00 »

February Existing Home…

ZUO

Zuora

$24.34

(0.00%)

, NKE

Nike

$88.05

(0.00%)

09:40
03/22/19
03/22
09:40
03/22/19
09:40
Options
Unusually active option classes on open March 22nd »

Unusual total active…

ZUO

Zuora

$24.34

(0.00%)

NKE

Nike

$88.05

(0.00%)

TIF

Tiffany

$100.07

(0.00%)

NOK

Nokia

$6.26

(0.00%)

TME

Tencent Music

$17.44

(0.00%)

MRVL

Marvell

$20.80

(0.00%)

BBY

Best Buy

$70.56

(0.00%)

TWTR

Twitter

$32.61

(0.00%)

AAPL

Apple

$195.07

(0.00%)

PBR

Petrobras

$17.05

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 22

    Mar

  • 25

    Mar

  • 25

    Mar

  • 27

    Mar

  • 04

    Apr

  • 04

    Apr

  • 04

    Apr

  • 15

    Apr

  • 23

    Apr

  • 23

    Apr

  • 20

    May

MDT

Medtronic

$92.09

0.83 (0.91%)

09:37
03/22/19
03/22
09:37
03/22/19
09:37
Conference/Events
Medtronic management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 18

    May

  • 28

    May

LC

LendingClub

$3.00

0.065 (2.22%)

09:35
03/22/19
03/22
09:35
03/22/19
09:35
Conference/Events
LendingClub management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 01

    Apr

  • 02

    Apr

  • 28

    May

GVA

Granite Construction

$45.76

0.39 (0.86%)

09:34
03/22/19
03/22
09:34
03/22/19
09:34
Recommendations
Granite Construction analyst commentary  »

MKM Partners lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

PPC

Pilgrim's Pride

$21.32

0.71 (3.44%)

09:34
03/22/19
03/22
09:34
03/22/19
09:34
Hot Stocks
Pilgrim's Pride says Jayson Penn to succeed Bill Lovette as CEO »

Pilgrim's Pride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KR

Kroger

$24.33

0.35 (1.46%)

09:33
03/22/19
03/22
09:33
03/22/19
09:33
Conference/Events
Kroger management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

EXPE

Expedia

$124.13

1.56 (1.27%)

09:30
03/22/19
03/22
09:30
03/22/19
09:30
Recommendations
Expedia analyst commentary  »

Expedia RNG trending in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
03/22/19
03/22
09:30
03/22/19
09:30
General news
U.S. Data Slate - Week of March 25: »

U.S. Data Slate - Week of…

09:30
03/22/19
03/22
09:30
03/22/19
09:30
General news
PMI Composite FLASH Manufacturing â€' Level to be reported at 09:45 »

March PMI Composite FLASH…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.